

CLEAN VERSION OF PENDING CLAIMS

13. A method of treating ulcers with lansoprazole which comprises administering to a human a therapeutically effective amount of optically pure *S*(-)-isomer of lansoprazole, or a pharmaceutically acceptable salt thereof.

14. The method of claim 13, wherein the amount of *S*(-) lansoprazole or a pharmaceutically acceptable salt thereof is greater than approximately 90% by weight of the total weight of lansoprazole.

15. The method of claim 13, wherein *S*(-) lansoprazole is administered orally in the form of a tablet or capsule.

16. The method of claim 15, wherein the amount of *S*(-) lansoprazole or a pharmaceutically acceptable salt thereof administered is from about 5 mg to about 180 mg per day.

17. A method of treating gastroesophageal reflux disease which comprises administering to a human a therapeutically effective amount of optically pure *S*(-)-isomer of lansoprazole, or a pharmaceutically acceptable salt thereof.

18. The method of claim 17, wherein the amount of *S*(-) lansoprazole or a pharmaceutically acceptable salt thereof is greater than approximately 90% by weight of the total weight of lansoprazole.

19. The method of claim 17, wherein *S*(-) lansoprazole is administered orally in the form of a tablet or capsule.

20. The method of claim 19, wherein the amount of *S*(-) lansoprazole or a pharmaceutically acceptable salt thereof administered is from about 5 mg to about 180 mg per day.

21. A method of treating a condition caused by or contributed to by gastric hypersecretion which comprises administering to a human a therapeutically effective amount of optically pure *S*(-)-isomer of lansoprazole, or a pharmaceutically acceptable salt thereof.

22. The method of claim 21, wherein the amount of *S*(-) lansoprazole or a pharmaceutically acceptable salt thereof is greater than approximately 90% by weight of the total weight of lansoprazole.

23. The method of claim 21, wherein *S*(-) lansoprazole is administered orally in the form of a tablet or capsule.

24. The method of claim 23, wherein the amount of *S*(-) lansoprazole or a pharmaceutically acceptable salt thereof administered is from about 5 mg to about 180 mg per day.

25. The method according to claim 21, wherein said condition is Zollinger-Ellison Syndrome.

A2
Cont

26. A method of treating psoriasis which comprises administering to a human a therapeutically effective amount of optically pure S(-) isomer of lansoprazole, or a pharmaceutically acceptable salt thereof.

27. The method of claim 26, wherein the amount of S(-) lansoprazole or a pharmaceutically acceptable salt thereof is greater than approximately 90% by weight of the total weight of lansoprazole.

28. The method of claim 26, wherein S(-) lansoprazole is administered orally in the form of a tablet or capsule.

29. The method of claim 28, wherein the amount of S(-) lansoprazole or a pharmaceutically acceptable salt thereof administered is from about 5 mg to about 180 mg per day.
